Companion for CAR-T Web Application (CC) for Lymphoma

Phase-Based Progress Estimates
University of California, San Francisco, San Francisco, CA
Lymphoma+5 More
Web Application - Other
All Sexes
What conditions do you have?

Study Summary

The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be able to assist with patient education and preparation, communication between patients and their multidisciplinary teams, and home-based toxicity monitoring.

Eligible Conditions

  • Lymphoma
  • Leukemia
  • Plasma Cell Dyscrasia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Up to 6 months

1 day
Percentage of participants agreeing or strongly agreeing with helpfulness of CC web application.
Up to 26 days
Number of times an Electronic immune effector-cell associated encephalopathy assessment (eICE) is reported
Number of times that temperature >= 38. degrees Celsius (°C) is reported
Up to 6 months
Percentage of participants who access all four CC web application modules at least once

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Companion for CAR-T Web Application (CC)
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Companion for CAR-T Web Application (CC) · No Placebo Group · N/A

Companion for CAR-T Web Application (CC)
Experimental Group · 1 Intervention: Web Application · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months
Closest Location: University of California, San Francisco · San Francisco, CA
Photo of San Francisco  1Photo of San Francisco  2Photo of San Francisco  3
2008First Recorded Clinical Trial
23 TrialsResearching Lymphoma
688 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of a hematologic malignancy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.